Background Heart-fatty acid binding protein (HFABP) has been recognized as a highly heart-specific marker. However, it is currently unknown that its HFABP is also closely related to the severity of COVID-19. Methods We retrospectively screened 46 patients who met our inclusion criteria within 4 weeks. They were tested for HFABP after the diagnosis of COVID-19, and monitored for HFABP during their hospital stay. We tracked the patients during their hospital stay to determine if they had severe COVID-19 or mild-to-severe transition features. We calculated the chi-square test values found for HFABP to predict the correlation between HFABP levels and the severity of the COVID-19. Results Of these 46 cases, 16 cases with confirmed COVID-19 were tested for HFABP> 7 ng / mL upon admission; among them, 14 cases were diagnosed with severe COVID-19 within the hospitalization. The Odds ratio of the measured HFABP elevation was 6.81(95% confidence interval [CI] 5.23–8.40), and 3 patients with severe COVID-19 progressed in 5 patients with mild HFABP> 7 ng/mL. Conclusion These data indicate that the elevation of HFABP is closely related to the severity of COVID-19 in the patients, and the elevated HFABP may cause rapid development of patients with mild COVID-19 into severe COVID-19. But serum HFABP negative maybe make patients with mild COVID-19 safer, the current data show no effect on the all-cause mortality. Trial registration Our study has been registered with the Chinese Clinical Trial Registry, the registration number: ChiCTR2000029829 .
【초록키워드】 COVID-19, severe COVID-19, Hospitalization, severity, Protein, serum, Features, severity of COVID-19, clinical, Patient, Mild, correlation, registry, patients, predict, binding, marker, Hospital stay, chi-square test, confidence interval, all-cause mortality, inclusion criteria, Chinese, Registered, Result, tested, the patient, diagnosed, elevated, screened, calculated, determine, diagnosis of COVID-19, progressed, 【제목키워드】 Protein, heart, binding, case-control study, fatty,